| Literature DB >> 34613995 |
John B O'Connor1, Madison M Mottlowitz1, Brandie D Wagner2,3, Kathleen L Boyne1,4,5, Mark J Stevens2, Charles E Robertson2, Jonathan K Harris2, Theresa A Laguna1,4,5.
Abstract
RATIONALE: Chronic airway infection and inflammation resulting in progressive, obstructive lung disease is the leading cause of morbidity and mortality in cystic fibrosis. Understanding the lower airway microbiota across the ages can provide valuable insight and potential therapeutic targets.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34613995 PMCID: PMC8494354 DOI: 10.1371/journal.pone.0257838
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Study population.
| DCs (n = 128) | CF (n = 63) | P-value | |
|---|---|---|---|
|
| 5.2 (0–21.0) | 9.7 (0.9–19.7) | <0.001 |
| | 38 (30%) | 3 (5%) | <0.001 |
| | 31 (24%) | 9 (14%) | |
| | 32 (25%) | 25 (40%) | |
| | 17 (13%) | 21 (33%) | |
| | 10 (8%) | 5 (8%) | |
|
| 60 (47%) | 41 (65%) | 0.018 |
|
| 18.2 (4.2–78.3) (N = 128) | 29.0 (13.5–74.7) (N = 49) | <0.001 |
|
| 106.0 (51.0–181.0) (N = 120) | 132.4 (97.8–175.4) (N = 49) | <0.001 |
|
| N/A | N = 62 | N/A |
|
| N/A | 36 (58%) | N/A |
|
| N/A | 22 (35%) | N/A |
|
| N/A | 4 (6%) | N/A |
| 83.0 (41.0–109.0) (N = 27) | 86.5 (35.0–131.0) (N = 50) | 0.709 | |
|
| N = 126 | N = 53 | N/A |
|
| 213 (0–8122) (N = 126) | 1312 (66–51500) (N = 53) | <0.001 |
|
| 8 (1–99) (N = 107) | 80 (3–99) (N = 51) | <0.001 |
|
| 9 (1–66) (N = 155) | 3 (0–28) (N = 39) | <0.011 |
|
| N = 128 | N = 31 | N/A |
|
| 86 (67%) | 3 (10%) | <0.001 |
|
| 2 (2%) | 7 (23%) | 0.036 |
|
| 4 (3%) | 19 (61%) | <0.001 |
|
| 0 (0%) | 1 (3%) | 0.456 |
|
| 4 (3%) | 2 (6%) | 0.281 |
|
| 0 (0%) | 2 (6%) | 0.204 |
|
| 0 (0%) | 1 (3%) | 0.456 |
|
| 0 (0%) | 0 (0%) | ___ |
|
| 1 (2%) (N = 52) | 2 (3%) (N = 58) | 0.398 |
|
| 35 (90%) (N = 39) | 28 (45%) (N = 62) | <0.001 |
Data are presented as n, median (range) or n (%), unless otherwise stated. CF: Cystic fibrosis; FEV1: Forced expiratory volume in 1 s; BALF: Bronchoalveolar lavage fluid; MSSA: Methicillin-susceptible Staphylococcus aureus; MRSA: Methicillin-resistant Staphylococcus aureus.
* P-value calculated using Fisher’s exact test
Fig 1Load across age.
(A) Bar plots of TBL in CF and DCs in age groups, sample sizes are displayed along the x-axis and asterisks represent significant differences between CF and DC samples (B) TBL across the age spectrum with cubic B spline fitting (solid line) and 95% confidence intervals (shaded areas). On average BALF samples from CF subjects have higher TBL compared to DC samples, this is more pronounced during early school age and adolescence.
Fig 2Diversity across age.
(A) Bar plots comparing Shannon diversity index between CF and DCs at different ages, sample sizes are displayed along the x-axis and asterisks represent significant differences between CF and DC samples, and (B) Shannon diversity across the age spectrum. On average BALF samples from CF subjects have lower diversity compared to DCs, this is more pronounced starting at 1 year of age.
Fig 3Relative abundance across age.
Heatmap of sequencing results for all BALF samples in CF and DC groups with samples arranged in order of increasing age (in years). Taxa that had a relative abundance of over 40% in at least one of the samples are included. Clear distinctions in microbiota across the age spectrum are seen, with any taxa identified in high relative abundance in CF samples being seen in low relative abundance in DC samples (Staphylococcus aureus, Stenotrophomonas) and any taxa observed in low relative abundance in CF samples seen in high abundance in DC samples (Streptococcus mitis group).
Fig 4Neutrophilic inflammation.
Percent neutrophils across the spectrum of bacterial burden. Notable differences are seen between CF and DC subjects. While CF subjects have heightened percent neutrophils regardless of load, DCs exhibit a stronger linear relationship between percent neutrophils and bacterial burden.